Logo

Exosome Diagnostics, Amgen Partner on Liquid Biopsy Dx

Oct 03, 2016 | staff reporter

NEW YORK (GenomeWeb) – Exosome Diagnostics announced today that it has partnered with Amgen to develop a liquid biopsy test.

Under the terms of the deal, the companies will use Exosome's technology to identify a potential liquid biopsy diagnostic that may be used in Amgen's drug development processes. Additional terms of the arrangement were not disclosed.

The deal is the latest big pharma alliance for Exosome and follows a June agreement under which the company is developing an exosomal RNA sequencing platform for biomarker discovery with Takeda Pharmaceuticals.

Filed under

Molecular Diagnostics
Business News
Liquid Biopsy
Amgen
Exosome Diagnostics
Breaking News
The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.